Is Cassava Sciences Back in the Game?

Last week, biotech Cassava Sciences (NASDAQ: SAVA) published topline interim-analysis data for simufilam, a potential treatment for Alzheimer's disease. This is the company's sole late-stage candidate. The stock surged over 20% in pre-market trading on the news Wednesday, only to lose all of its gains and then some. The stock closed Wednesday down 1% to $52.31 and traded up over 23% on Friday to $64.40.

The company was recently hit by allegations from short-sellers, so it needed an opportunity like this to defend itself. Unfortunately, these developments do not paint a clear path to victory, but instead, they raise more perplexing questions about its science. Let's find out why.

Image source: Getty Images.

Source Fool.com